• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avinger Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/31/24 7:22:35 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email
    avgr20241231_8k.htm
    false 0001506928 0001506928 2024-12-29 2024-12-29
     
     
    --12-31
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     

     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
     
    December 29, 2024
     

     
    Avinger, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-36817
    20-8873453
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
     
    400 Chesapeake Drive
    Redwood City, California 94063
    (Address of principal executive offices, including zip code)
     
    (650) 241-7900
    (Registrant’s telephone number, including area code)
     
    Not Applicable
    (Former name or former address, if changed since last report.)
     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class:
     
    Trading Symbol(s):
     
    Name of each exchange on which registered:
    Common Stock, par value $0.001 per share
     
    AVGR
     
    The Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 3.02. Unregistered Sales of Equity Securities
     
    The Certificate of Designation of Preferences, Rights and Limitations (the “Series E Certificate of Designation”) of Series E Convertible Preferred Stock (the “Series E Preferred Stock”) of Avinger, Inc. (the “Company”) entitles the holders of Series E Preferred Stock to dividends (the “Series E Preferred Dividend”) on each share of Series E Preferred Stock at a rate of 8% of $1,000 per annum, compounded annually. The Series E Certificate of Designation allows the Company to pay the Series E Preferred Dividends by issuing and delivering fully paid and nonassessable shares of Series E Preferred Stock. Accordingly, on December 29, 2024, the Board of Directors of the Company declared a Series E Preferred Dividend on the Series E Preferred Stock of an aggregate of 156 shares of Series E Preferred Stock to pay the Series E Preferred Dividend to the holders of record of Series E Preferred Stock as of December 31, 2024.
     
    The Certificate of Designation of Preferences, Rights and Limitations (the “Series F Certificate of Designation”) of Series F Convertible Preferred Stock (the “Series F Preferred Stock”) of Avinger, Inc. entitles the holders of Series F Preferred Stock to dividends (the “Series F Preferred Dividend”) on each share of Series F Preferred Stock at a rate of 5% of $1,000 per annum until the third anniversary of the issuance date of the Series F Preferred Stock, compounded annually. The Series F Certificate of Designation allows the Company to pay the Series F Preferred Dividends by issuing and delivering fully paid and nonassessable shares of Series F Preferred Stock. Accordingly, on December 29, 2024, the Board of Directors of the Company declared a Series F Preferred Dividend on the Series F Preferred Stock of an aggregate of 298 shares of Series F Preferred Stock to pay the Series F Preferred Dividend to the holders of record of Series F Preferred Stock as of December 31, 2024, subject to approval by the holders of the Series E Preferred Stock of the issuance of the shares of Series F Preferred Stock, which rank pari passu with the shares of Series E Preferred Stock, and the amendment of the Series F Certificate of Designation as described in Item 3.03 below.
     
    The Certificate of Designation of Preferences, Rights and Limitations (the “Series H Certificate of Designation”) of Series H Convertible Preferred Stock (the “Series H Preferred Stock”) of Avinger, Inc. entitles the holders of Series H Preferred Stock to dividends (the “Series H Preferred Dividend,” together with the Series E Preferred Dividend and Series F Preferred Dividend, the “Preferred Dividends”) on each share of Series H Preferred Stock at a rate of 8% of $1,000 per annum, compounded annually. The Series H Certificate of Designation allows the Company to pay the Series H Preferred Dividends by issuing and delivering fully paid and nonassessable shares of Series H Preferred Stock. Accordingly, on December 29, 2024, the Board of Directors of the Company declared a Series H Preferred Dividend on the Series H Preferred Stock of an aggregate of 552 shares of Series H Preferred Stock to pay the Series H Preferred Dividend to the holders of record of Series H Preferred Stock as of December 31, 2024, subject to approval by the holders of the Series F Preferred Stock of the issuance of the shares of Series H Preferred Stock, which rank senior in preference to the Series F Preferred Stock.
     
    The Company paid the Preferred Dividends on December 31, 2024.
     
    The Company relied on the exemption from registration available under Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933, as amended, in connection with the distributions.
     
     

     
     
    Item 3.03. Material Modification to Rights of Securityholders.
     
    On December 31, 2024, the Company filed a Certificate of Amendment to the Designated Number of Shares of Series F Convertible Preferred Stock (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of designated shares of Series F Preferred Stock from 7,224 to 10,000.
     
    The Amendment was approved by the Company’s board of directors and the requisite holders of outstanding shares of Series E Preferred Stock and Series F Preferred Stock. No approval of the holders of the Company’s common stock was required to effectuate the Amendment.
     
    The Amendment became effective upon filing. Other than the Amendment described above, the rights, preferences and privileges of the Series F Preferred Stock remain unchanged, and the description of such stock is qualified in its entirety by the copy of the Series F Certificate of Designation filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 7, 2024. The foregoing description of the Amendment is not complete and is subject to and qualified in its entirety by reference to the Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
     
    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference. 
     
    Item 5.07. Submission of Matters to a Vote of Security Holders.
     
    On December 31, 2024, the holders of all of the outstanding shares of the Series E Preferred Stock approved the issuance of shares of Series F Preferred Stock and the Amendment by written consent as described above, and the Series F Preferred Stock approved the issuance of the shares of Series H Preferred Stock and the Amendment by written consent, as set forth above.
     
    The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference. 
     
    Item 9.01.  Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit No.
     
    Description
    3.1
     
    Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock, as filed with the Secretary of State of the State of Delaware on December 31, 2024.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
       
    AVINGER, INC.
           
           
    Date: December 31, 2024
    By:
    /s/ Jeffrey M. Soinski
     
       
    Jeffrey M. Soinski
    Chief Executive Officer
     
     
     
    Get the next $AVGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVGR

    DatePrice TargetRatingAnalyst
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    6/29/2021$2.50Buy
    B. Riley Securities
    More analyst ratings

    $AVGR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.

    SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)

    2/14/25 5:07:21 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Avinger Inc (0001506928) (Filer)

    2/10/25 5:01:26 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Avinger Inc (0001506928) (Filer)

    2/5/25 5:00:31 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:35:20 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:34:44 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)

    4 - Avinger Inc (0001506928) (Issuer)

    1/24/25 9:34:02 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Avinger with a new price target

    Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously

    11/15/21 12:33:44 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Avinger with a new price target

    B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50

    6/29/21 6:16:21 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    11/7/24 4:05:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    10/29/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

    REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

    10/24/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Financials

    Live finance-specific insights

    View All

    Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    11/7/24 4:05:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    10/29/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Avinger to Announce Second Quarter 2024 Results on August 8, 2024

    REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

    7/29/24 8:45:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Leadership Updates

    Live Leadership Updates

    View All

    Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

    REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

    8/5/24 8:00:00 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Avinger Announces Annual Meeting Results

    REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

    12/23/20 4:50:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    11/14/24 3:23:30 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avinger Inc.

    SC 13G/A - Avinger Inc (0001506928) (Subject)

    11/13/24 11:13:40 AM ET
    $AVGR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avinger Inc.

    SC 13G - Avinger Inc (0001506928) (Subject)

    6/21/24 4:45:23 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care